Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin (BCG), the active ingredient in Oncotice, is a live‑attenuated bacterial vaccine presented as a suspension for intravesical use. It is employed in the treatment of non‑muscle‑invasive bladder cancer, primarily in patients who have undergone transurethral resection of the tumour. GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

Oncotice is a live‑attenuated BCG vaccine used within the uro‑oncology pathway.

- Non‑muscle‑invasive bladder cancer: reduces recurrence and progression after tumour resection. - Carcinoma in situ of the bladder: induces immune‑mediated tumour control. - High‑risk recurrent bladder tumours: provides additional prophylactic benefit following intravesical therapy.

Adverse reactions are primarily local and systemic immune responses.

Common Side Effects: - Cystitis‑like symptoms: urgency, frequency, dysuria. - Mild haematuria: small amounts of blood in urine. - Low‑grade fever: transient temperature rise. - Fatigue: general tiredness. - Local irritation: bladder discomfort. - Flu‑like symptoms: chills and muscle aches.

Serious or Rare Side Effects: - Systemic BCG infection (disseminated BCGitis): fever, weight loss, organ involvement. - Severe allergic reaction: anaphylaxis, airway swelling. - Persistent high‑grade fever lasting >48 h. - Sepsis or septic shock. - Renal impairment or obstructive uropathy. - Life‑threatening haematuria requiring intervention.

Before administering Oncotice, clinicians should evaluate patient suitability and monitor for adverse events.

- Contraindication: active tuberculosis or immunosuppression: avoid use due to infection risk. - Prior BCG therapy reaction: assess severity before repeat dosing. - Urinary tract infection: treat and resolve before instillation. - Bladder trauma or recent surgery: postpone until healing. - Pregnancy: avoid use; potential fetal risk unknown. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Oncotice may interact with other agents that modify immune function or cause urinary irritation.

Major Interactions (Avoid): - Systemic immunosuppressants: cyclophilic   - Cytotoxic chemotherapy   - High‑dose corticost  

Moderate   - Antifungal   - Antiviral   t